Sei Investments Co. Sells 31,743 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Sei Investments Co. cut its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 48.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 34,456 shares of the company's stock after selling 31,743 shares during the period. Sei Investments Co.'s holdings in IDEXX Laboratories were worth $14,244,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Flossbach Von Storch SE grew its position in IDEXX Laboratories by 5,439.3% in the fourth quarter. Flossbach Von Storch SE now owns 473,336 shares of the company's stock worth $195,696,000 after acquiring an additional 464,791 shares in the last quarter. William Blair Investment Management LLC boosted its holdings in shares of IDEXX Laboratories by 701.6% in the 4th quarter. William Blair Investment Management LLC now owns 422,133 shares of the company's stock worth $174,527,000 after purchasing an additional 369,471 shares in the last quarter. Assenagon Asset Management S.A. increased its position in shares of IDEXX Laboratories by 265.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company's stock valued at $179,867,000 after purchasing an additional 316,048 shares during the last quarter. Seilern Investment Management Ltd purchased a new position in shares of IDEXX Laboratories during the 4th quarter valued at about $113,104,000. Finally, Vontobel Holding Ltd. boosted its stake in IDEXX Laboratories by 90.1% in the fourth quarter. Vontobel Holding Ltd. now owns 418,563 shares of the company's stock worth $173,051,000 after buying an additional 198,404 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

Remove Ads

IDEXX Laboratories Trading Down 0.1 %

Shares of IDEXX Laboratories stock traded down $0.44 during midday trading on Tuesday, reaching $419.52. 285,500 shares of the company's stock traded hands, compared to its average volume of 582,127. The stock has a 50 day moving average of $437.08 and a 200-day moving average of $442.03. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $548.88. The company has a market cap of $34.01 billion, a PE ratio of 39.32, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31.

Wall Street Analysts Forecast Growth

Several research firms have commented on IDXX. Leerink Partnrs raised shares of IDEXX Laboratories to a "strong-buy" rating in a research note on Monday, December 2nd. Leerink Partners began coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They issued an "outperform" rating and a $500.00 price target for the company. Bank of America raised their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research note on Tuesday, February 4th. StockNews.com lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Tuesday, March 25th. Finally, Piper Sandler raised their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research report on Monday, February 10th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, IDEXX Laboratories currently has a consensus rating of "Moderate Buy" and a consensus price target of $533.75.

Insider Activity at IDEXX Laboratories

In related news, EVP George Fennell sold 9,986 shares of the company's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares of the company's stock, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director M Anne Szostak sold 3,000 shares of the firm's stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares of the company's stock, valued at $1,426,242.34. This represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by corporate insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.